Investseekers reports the CHMP backed orforglipron, making it the second oral weight loss pill to get the nod after Novo's oral Wegovy.
Recap by typeshit. Post by Investseekers on X.
Lilly's tirzepatide shot Zepbound now has FDA approval in a KwikPen format for weight management. Tap through for details on the new pen.
At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
Polish pharmacy platform GdziePoLek says, citing the manufacturer, that the first Oral Wegovy shipment should arrive soon. No exact launch date is set yet.
A short clip from Dr. Reese pushing back on the rush toward peptides as an easy shortcut, with little detail beyond that.
The once-weekly autoinjector is cleared for type 2 diabetes, overweight and obesity. Lilly never officially sold Mounjaro in Russia, and its rights there ended in November 2024.
The Indore maker wants a drug company to license the formula. It admits the combination has never been tested alongside a GLP-1 drug.
Loading…